ARCHON-1 trial: what clinicians have said so far
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
- NCT03801902 ↗
- Completed
- National Cancer Institute (NCI)
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on ARCHON-1 (monalizumab plus durvalumab; oleclumab plus durvalumab; durvalumab in PD-L1 high locally advanced non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 10 most recent indexed sources
Automated from the 10 newest of 11 indexed sources (Feb 2019 – Dec 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether durvalumab with radiotherapy alone can match concurrent chemoradiotherapy followed by consolidation durvalumab
- Whether accelerated hypofractionated radiotherapy with durvalumab performs as well as conventional fractionation
- Whether high PD-L1 expression is a sufficient basis for omitting concurrent chemotherapy
Indexed commentary on ARCHON-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 11 posts on X, typically up to 48 once built |
The trial
ClinicalTrials.gov- Official title
- Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma; Locally Recurrent Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma
- Interventions
- Accelerated Hypofractionated Radiation Therapy; Biospecimen Collection; Computed Tomography; Durvalumab; Magnetic Resonance Imaging of the Brain with and without Contrast; Monalizumab; Oleclumab; Radiation Therapy
- Arms
- Arm I (CLOSED) (Durvalumab and ACRT) · Experimental
- Arm II (CLOSED) (Durvalumab and standard RT) · Experimental
- Arm III (durvalumab, monalizumab, standard RT) · Experimental
- Arm IV (durvalumab, oleclumab, standard RT) · Experimental
- Enrollment
- 26
- Primary outcomes
- Number of Participants Experiencing a Safety Event
- Sponsor
- National Cancer Institute (NCI) with NRG Oncology
- Start
- Oct 28, 2019
- Primary completion
- Oct 26, 2021
- Results posted
- Yes
- Registry record
- NCT03801902 · updated Sep 23, 2025